RT @RichardPAConway: Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly app
Tweet Content
Teng et al BLISS-BELIEVE Biomarker outcome RCT Sequential belimumab-rituximab in SLE. Certainly appears to be a serologic benefit on dsDNA, C3/4. But we need clinical parameters to correlate with this. @RheumNow #EULAR2022 OP0281 https://t.co/iEeSN0SNcr https://t.co/HN8ya4QZLU
Links
EULAR Abstract Archive
http://scientific.sparx-ip.net/archiveeular/index.cfm?view=1&searchfor=OP0281&c…
Show on Archive Page
On
Display in Search Results
On
PDQ
Off